Aytu BioPharma, Inc. (AYTU) has a negative trailing P/E of -1.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 8.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -91.46%, forward earnings yield 11.98%.
Criteria proven by this page:
Overall SharesGrow Score: 50/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -0.3 | 0.00 | 0.81 | 3.18 | - |
| 2017 | -0.2 | 0.00 | 1.37 | 1.71 | - |
| 2018 | -0.3 | 0.00 | 0.26 | 0.95 | - |
| 2019 | -0.3 | 0.01 | 2.11 | 2.04 | - |
| 2020 | -4.8 | 0.05 | 0.69 | 2.36 | - |
| 2021 | -1.4 | -0.09 | 0.61 | 1.28 | - |
| 2022 | -0.2 | -0.03 | 0.46 | 0.21 | - |
| 2023 | -0.3 | 0.00 | 0.14 | 0.05 | - |
| 2024 | -1.0 | 0.02 | 0.57 | 0.24 | - |
| 2025 | -1.0 | 0.04 | 0.72 | 0.21 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1,294,740.00 | $2.56M | $-28.18M | -1099.7% |
| 2017 | $-193,194.00 | $3.22M | $-22.51M | -698.7% |
| 2018 | $-3,061.23 | $3.66M | $-10.19M | -278.4% |
| 2019 | $-1,210.28 | $7.32M | $-47.17M | -644.3% |
| 2020 | $-60.20 | $27.63M | $-13.62M | -49.3% |
| 2021 | $-69.60 | $65.63M | $-58.29M | -88.8% |
| 2022 | $-74.01 | $96.67M | $-108.78M | -112.5% |
| 2023 | $-5.11 | $107.4M | $-17.05M | -15.9% |
| 2024 | $-2.86 | $81M | $-15.84M | -19.6% |
| 2025 | $-2.16 | $66.38M | $-13.56M | -20.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.24 | $-1.40 – $-1.14 | $57.06M | $53.69M – $62.74M | 1 |
| 2027 | $-0.23 | $-0.26 – $-0.21 | $81.4M | $76.59M – $89.5M | 1 |
| 2028 | $0.31 | $0.29 – $0.35 | $94.5M | $88.92M – $103.91M | 1 |
